Centogene N.V. – NASDAQ:CNTG
Centogene N.V. stock price monthly change
Centogene N.V. stock price quarterly change
Centogene N.V. stock price yearly change
Centogene N.V. key metrics
Market Cap | 9.42M |
Enterprise value | 26.03M |
P/E | -0.35 |
EV/Sales | 0.27 |
EV/EBITDA | -0.97 |
Price/Sales | 0.15 |
Price/Book | 0.71 |
PEG ratio | N/A |
EPS | N/A |
Revenue | N/A |
EBITDA | N/A |
Income | N/A |
Revenue Q/Q | -100% |
Revenue Y/Y | -51.37% |
Profit margin | -53.66% |
Oper. margin | -58.14% |
Gross margin | 16.41% |
EBIT margin | -58.14% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCentogene N.V. stock price history
Centogene N.V. stock forecast
Centogene N.V. financial statements
| Dec 2022 | 13.04M | -7.81M | -59.94% |
|---|---|---|---|
| Mar 2023 | 12.31M | -12.22M | -99.32% |
| Jun 2023 | 12.31M | -12.22M | -99.32% |
| Sep 2023 | 0 | 0 |
| 2023-05-16 | -0.43 | -0.58 |
|---|
| Apr 2023 | 71892000 | 87.11M | 121.17% |
|---|---|---|---|
| Jun 2023 | 71892000 | 87.11M | 121.17% |
| Sep 2023 | 0 | 0 | |
| Dec 2023 | 77155000 | 102.43M | 132.77% |
| Dec 2022 | -5.66M | -259K | 7.62M |
|---|---|---|---|
| Mar 2023 | -7.24M | -1.07M | -2.59M |
| Jun 2023 | -7.24M | -1.07M | -2.59M |
| Sep 2023 | 0 | 0 | 0 |
Centogene N.V. alternative data
| Aug 2023 | 444 |
|---|---|
| Sep 2023 | 444 |
| Oct 2023 | 444 |
| Nov 2023 | 444 |
| Dec 2023 | 444 |
| Jan 2024 | 444 |
| Feb 2024 | 444 |
| Mar 2024 | 444 |
| Apr 2024 | 444 |
| May 2024 | 444 |
| Jun 2024 | 444 |
| Jul 2024 | 384 |
Centogene N.V. other data
| Quarter | Transcript |
|---|---|
| Q4 2021 30 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 24 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Q2 2021 7 Sep 2021 | Q2 2021 Earnings Call Transcript |
| Q4 2020 15 Apr 2021 | Q4 2020 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Volkmar Weckesser Ph.D. (1968) Chief Information Officer & Member of Management Board | $875,900 |
Dr. Andrin Oswald M.D., Ph.D. (1972) Executive Officer | $515,370 |
-
When is Centogene N.V.'s next earnings date?
Unfortunately, Centogene N.V.'s (CNTG) next earnings date is currently unknown.
-
Does Centogene N.V. pay dividends?
No, Centogene N.V. does not pay dividends.
-
How much money does Centogene N.V. make?
Centogene N.V. has a market capitalization of 9.42M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 0.14% to 47.54M US dollars. Centogene N.V. made a loss 34.8M US dollars in net income (profit) last year or -$0.58 on an earnings per share basis.
-
What is Centogene N.V.'s stock symbol?
Centogene N.V. is traded on the NASDAQ under the ticker symbol "CNTG".
-
What is Centogene N.V.'s primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of Centogene N.V.?
Shares of Centogene N.V. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Centogene N.V.'s key executives?
Centogene N.V.'s management team includes the following people:
- Dr. Volkmar Weckesser Ph.D. Chief Information Officer & Member of Management Board(age: 57, pay: $875,900)
- Dr. Andrin Oswald M.D., Ph.D. Executive Officer(age: 53, pay: $515,370)
-
How many employees does Centogene N.V. have?
As Jul 2024, Centogene N.V. employs 384 workers, which is 14% less then previous month and 14% less then previous quarter.
-
When Centogene N.V. went public?
Centogene N.V. is publicly traded company for more then 5 years since IPO on 7 Nov 2019.
-
What is Centogene N.V.'s official website?
The official website for Centogene N.V. is centogene.com.
-
How can i contact Centogene N.V.?
Centogene N.V. can be reached via phone at +49 381 80113500.
Centogene N.V. company profile:
Centogene N.V.
centogene.comNASDAQ
384
Medical - Diagnostics & Research
Healthcare
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including PCR and antigen testing services. It has collaboration and license agreements with Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
Rostock, 18055
CIK: 0001757097
ISIN: NL0014040206
CUSIP: N1976T109
